Ciprofloxacin extended release - Depomed

Drug Profile

Ciprofloxacin extended release - Depomed

Alternative Names: Ciprofloxacin controlled release - Depomed; Ciprofloxacin gastric retention; Ciprofloxacin GR; Ciprofloxacin hydrochloride prolonged-release tablets - DepoMed; Proquin XR; URITENT; UTIMINX

Latest Information Update: 12 Mar 2015

Price : $50

At a glance

  • Originator Depomed
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Urinary tract infections

Highest Development Phases

  • Market Withdrawal Urinary tract infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Oct 2010 Withdrawn for Urinary tract infections in USA (PO)
  • 24 Jul 2008 Registered for Urinary tract infections in Sweden (PO, Controlled release, 500mg, Once daily)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top